Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanomaAlice Indini, Michele Del Vecchio, Filippo de Braud et al.|Journal of Cancer Research and Clinical Oncology|2018Cited by 200
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohortPaolo A. Ascierto, Paola Queirolo, Ruggero Ridolfi et al.|Journal of Translational Medicine|2014Cited by 164
Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access ProgramPaolo A. Ascierto, Michele Maio, Francesco De Rosa et al.|Cancer Investigation|2014Cited by 105
The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line TherapyGiovanni Fucà, Michele Del Vecchio, Teresa Beninato et al.|Targeted Oncology|2021Cited by 61
Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experienceAlice Indini, Michele Del Vecchio, Lorenza Di Guardo et al.|Journal of Gynecologic Oncology|2019Cited by 59